Capital Research Global Investors
ALXN

Capital Research Global Investors’s Alexion Pharmaceuticals ALXN Stock Holding History

Capital Research Global Investors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-144,486
Closed -$17.3M – 462
2017
Q4 		$17.3M Buy
144,486
+423
+0.3% +$51.5K 0.01% 386
2017
Q3 		$20.2M Buy
144,063
+1,868
+1% +$254K 0.01% 381
2017
Q2 		$17.3M Buy
142,195
+970
+0.7% +$113K 0.01% 386
2017
Q1 		$17.1M Sell
141,225
-7,149,175
-98% -$922M 0.01% 387
2016
Q4 		$892M Sell
7,290,400
-8,014,731
-52% -$981M 0.29% 91
2016
Q3 		$1.88B Sell
15,305,131
-10,284,191
-40% -$1.32B 0.62% 43
2016
Q2 		$2.99B Sell
25,589,322
-2,012,885
-7% -$286M 1.02% 22
2016
Q1 		$3.84B Hold
27,602,207
– – 1.32% 12
2015
Q4 		$5.27B Buy
27,602,207
+194,323
+0.7% +$33.9M 1.8% 8
2015
Q3 		$4.29B Buy
27,407,884
+1,074,143
+4% +$196M 1.53% 10
2015
Q2 		$4.76B Buy
26,333,741
+1,570,549
+6% +$271M 1.56% 11
2015
Q1 		$4.29B Buy
24,763,192
+473,092
+2% +$85.6M 1.47% 10
2014
Q4 		$4.49B Buy
24,290,100
+49,800
+0.2% +$9.23M 1.53% 11
2014
Q3 		$4.02B Buy
24,240,300
+10,235
+0% +$1.68M 1.39% 12
2014
Q2 		$3.79B Buy
24,230,065
+745,592
+3% +$118M 1.32% 13
2014
Q1 		$3.57B Sell
23,484,473
-218,639
-0.9% -$34.8M 1.29% 12
2013
Q4 		$3.15B Buy
23,703,112
+1,498,586
+7% +$180M 1.17% 13
2013
Q3 		$2.58B Buy
22,204,526
+776,426
+4% +$85.2M 1.02% 19
2013
Q2 		$1.98B Buy
+21,428,100
New +$2.06B 0.84% 25

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Capital Research Global Investors's ALXN Position: Q1 2018 in Review

Capital Research Global Investors sold out of Alexion Pharmaceuticals (ALXN) in Q1 2018, closing a stake of 144,486 shares — an estimated $17.3M sold.

Capital Research Global Investors first reported a position in ALXN in Q2 2013 and held it in 19 quarters. The position peaked at $5.27B in Q4 2015. 597 funds tracked by Wall St. Rank hold ALXN as of Q1 2018.

  • Capital Research Global Investors reported no remaining Alexion Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Capital Research Global Investors sold 144,486 Alexion Pharmaceuticals shares in Q1 2018, an estimated $17.3M.
  • Capital Research Global Investors first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 19 quarters.
  • Capital Research Global Investors's Alexion Pharmaceuticals position peaked at $5.27B in Q4 2015.
  • 597 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2018.

Based on Capital Research Global Investors's 13F filing for Q1 2018, filed 15 May 2018.